$150.78
− 0.44− 0.29%
FinnhubUpdated 19:01
No data
No data
This data isn't available right now.
Balance-sheet ratios aren't available for this company.
It is an automated pre-screen based on the line of business and AAOIFI's widely used financial thresholds; a final judgement rests with your own school of thought and the certification boards that audit the filings.
The interest-income test (5% of revenue) needs a revenue breakdown our free data source doesn't provide, so that criterion isn't screened.
Gilead, the biotech — leader in HIV therapy, growing in oncology and long-acting HIV prevention (lenacapavir).
CacheUpdated 18:12May Be Out Of Date
Average close over the last 50, 100 and 200 trading days. The percentage next to it is how far the current price sits from that average.
| Period | Report Date | Surprise | EPS · Forecast | EPS · Actual | Revenue · Forecast | Revenue · Actual |
|---|---|---|---|---|---|---|
| Jun 202608/04/2026 | + 8.53% | − $7.38 | − $6.75 | |||
| Mar 202603/31/2026 | + 3.97% | $1.95 | $2.03 | |||
| Dec 202512/31/2025 | + 0.73% | $1.85 | $1.86 | |||
| Sep 202509/30/2025 | + 13.68% | $2.17 | $2.47 |
EPS (Earnings Per Share) is the company's quarterly net profit divided by its share count — how much profit a single share produced in that period. Analysts publish an estimate for each quarter, and the surprise is how far the reported figure landed above or below it. Revenue is total sales before profit: the market often sells a company that beats on earnings but misses on revenue, so the two are read together.
Couldn't load data
Industry: Biotechnology